Pascal Soriot is stuck in a Chinese limbo. In recent months, the CEO of $205 billion drug giant AstraZeneca has seen his ...

Verition Fund Management LLC lowered its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 66.0% in the third ...

The AstraZeneca share price is down almost 20% since September! What’s behind this drop, and where do analysts think the ...

AstraZeneca PLC AZN shares inched down 0.95% to £104.68 Friday, on what proved to be an all-around grim trading session for ...

The AstraZeneca PLC ADR AZN dropped 0.54% to $66.58 Friday, on what proved to be an all-around mixed trading session for the ...

▎药明康德内容团队编辑阿斯利康（AstraZeneca）宣布，其重磅免疫疗法Imfinzi（durvalumab）的补充生物制品许可申请（sBLA）已获美国FDA受理，并被授予优先审评资格，用于治疗肌层浸润性膀胱癌（MIBC）患者。FDA预计将在20 ...

NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ...

AstraZeneca on Wednesday named Iskra Reic as its new international executive vice president (EVP), taking over from Leon Wang ...

In a report released on December 11, David Evans from Kepler Capital maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

此次FDA授予突破性疗法认定主要是基于TROPION-Lung05临床2期试验数据，并加上TROPION-Lung01临床3期试验的支持性数据。今年美国临床肿瘤学会（ASCO）年会中所公布的TROPION-Lung05试验的部分结果显示，18名具有目 ...

Trying to break from the decade-old practice of using BTK inhibitors indefinitely to treat blood cancer, AstraZeneca has ...

The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...